Hereditary rickets revealed  by Portable, Anthony A. & Miller, Walter L.
EDITORIAL
Hereditary rickets revealed
The hormone 1,25-dihydroxyvitamin D [1,25(OH)2D]
plays an essential role in calcium metabolism, bone growth,
and cellular differentiation. The key rate-limiting, hormon-
ally-regulated step in the biosynthesis of 1,25(OH)2D is the
1a-hydroxylation of 25-hydroxyvitamin D (25-OH) that
occurs in the convoluted and straight portions of the
proximal renal tubule. This reaction is catalyzed by 25-
hydroxyvitamin D-1a-hydroxylase (1a-hydroxylase), a mi-
tochondrial cytochrome P450 enzyme that is subject to
complex regulation by parathyroid hormone, calcium,
phosphorus, and 1,25(OH)2D itself.
Synthesis of 1,25(OH)2D is impaired in numerous disor-
ders including chronic renal insufficiency, renal tubular
diseases such as Fanconi syndrome and X-linked hypophos-
phatemic rickets, and autosomal recessive 1a-hydroxylase
deficiency, which also is termed vitamin D-dependent
rickets type 1 or pseudovitamin D-deficiency rickets. This
rare disorder is characterized by failure to thrive, muscle
weakness, hypocalcemia, secondary hyperparathyroidism,
and the bony changes of rickets [1]. The hallmarks of the
disease are the finding of greatly reduced serum concen-
trations of 1,25(OH)2D despite normal or increased con-
centrations of 25-OHD, and the reversal of clinical and
laboratory abnormalities by administration of physiologic
amounts of 1,25(OH)2D3 [2–4]. It has been assumed that
the genetic defect results from defective renal 1a-hydroxy-
lation of 25-OHD [2]. Indeed, with the recent cloning of the
cDNA encoding 1a-hydroxylase, P450c1a, from human
keratinocytes [5] and kidney [6], rat kidney [7,8], and mouse
kidney [9], and cloning of the human gene [6,10,11],
mutations in the P450c1a gene have been directly demon-
strated in affected patients [5,6]. The human P450c1a gene
has been localized to chromosome 12 by analysis of rodent/
human somatic cell hybrids [5,10] and by fluorescence in
situ hybridization [6,7], consistent with the earlier mapping
of the disease to chromosome 12q14 by linkage analysis.
The catalytic activity 1a-hydroxylase, like that of all
mitochondrial P450 enzymes, requires the presence of two
cofactors, ferredoxin reductase and ferredoxin, which
transfer electrons from NADPH to the P450 itself, the
moiety that determines the enzyme’s specificity. Also re-
cently cloned are P450c25 (also termed P450c27), which
catalyzes the 25-hydroxylation of vitamin D and the 26- or
27-hydroxylation of bile acids in the liver, and P450c24, the
vitamin D 24-hydroxylase, which presumably initiates a
degradative pathway. Only five mitochondrial (Class 1)
P450 enzymes have been identified to date, three of which
are involved in the metabolism of vitamin D, the other two
being P450scc, the cholesterol side-chain cleavage enzyme,
and P450c11b-hydroxylase, and its isozyme P450c11AS, the
aldosterone synthase. Within the heme-binding region of
the enzyme, the amino acid sequence identity of P450c1a is
65 to 73% to that of human P450c25 and P450c24; however,
its overall identity to that of the other mitochondrial P450
enzymes is limited, 30 to 39% [5].
In this issue of Kidney International, Yoshida and associ-
ates [12] report the identification of two mutations in the
1a-hydroxylase gene in four patients with vitamin D-
dependent rickets type 1 who were of French-Canadian
ancestry, a population in which the disease occurs at an
unusually high frequency. Three patients were homozygous
for a single deletion/frameshift mutation and the fourth
patient was homozygous for a 7 bp insertion, both muta-
tions leading to premature termination of the protein.
Parents of the probands were heterozygous for the respec-
tive mutations and control subjects were homozygous for
the normal 1a-hydroxylase sequence. The authors state
that their identification of two different mutations in the
French-Canadian patients suggests that there is more than
one founder for the 1a-hydroxylase mutation in this popu-
lation. This is consistent with the findings of Labuda et al,
who performed linkage analysis of 32 affected French-
Canadian families [13]. These authors suggested that hap-
lotype analysis of three microsatellite markers, D12S90,
D12S305 and D12S104, could distinguish the allelic contri-
bution of various founder populations, and that patients
from the Charlevoix-Saguenay-Lac-Saint-Jean region of
Quebec and those from eastern Canada (Acadian) derived
from independent founder events. Because of the small
number of patients studied by Yoshida et al and the lack of
microsatellite haplotyping data, it cannot be determined
whether the two mutations they identified originate from
either the Charlevoix or the Acadian founder.
The present report adds to the growing list of identi-
fied mutations in the 1a-hydroxylase gene. The first muta-
tion was identified by Fu et al in an American girl with
vitamin D-dependent rickets type 1, who was a compound
heterozygote for two deletion/frameshift mutations in exon
Key words: vitamin D, heredity, failure to thrive, hypocalcemia, secondary
hyperparathyroidism.
© 1998 by the International Society of Nephrology
Kidney International, Vol. 54 (1998), pp. 1762–1764
1762
2 of the 1a-hydroxylase gene that resulted in premature
truncation of the protein [5]. Cultured skin keratinocytes
from the patient were devoid of 1a-hydroxylase activity,
providing the first direct proof that the keratinocyte and
renal 1a-hydroxylase enzymes are encoded by the same
gene. In four Japanese patients studied by Kitanaka and
colleagues, four different homozygous missense mutations
were identified, each of which abolished 1a-hydroxylase
activity as measured in COS-1 cells transfected with the
mutant cDNA [6]. The asymptomatic parents and sibling
were heterozygous for the mutations, demonstrating the
autosomal recessive inheritance of this disease. In studies
from our laboratory reported in preliminary form, we
identified 19 patients from 17 families representing various
ethnic groups, who were either homozygous or compound
heterozygous for 14 different mutations in the 1a-hydrox-
ylase gene [14]. Seven of the mutations were missense and
7 were deletions or insertions that resulted in premature
termination of the protein. None of the missense mutations
retained 1a-hydroxylase activity when measured in MA-10
cells transfected with the mutant cDNA. It is apparent from
the various reports that the severity of the P450c1a muta-
tion cannot be predicted from the clinical presentation of
the disease. Thus, data from three different laboratories to
date demonstrate that most if not all patients with 1a-
hydroxylase deficiency have severe mutations in the gene
encoding P450c1a. Hence, it is appropriate that the terms
“vitamin D-dependent rickets type 1” or “pseudovitamin
D-deficiency rickets” be abandoned in favor of the term
“1a-hydroxylase deficiency.”
The molecular genetic basis of two other inherited forms
of rickets has been determined. Vitamin D-dependent
rickets type 2, also termed hereditary vitamin D-resistant
rickets, is due to mutations in the gene for the vitamin D
receptor that result in impaired action of the hormone in
target tissues [15]. In patients with this disease or with
1a-hydroxylase deficiency, rickets occurs because of resis-
tance to or absolute deficiency of 1,25(OH)2D, respectively.
However, the molecular mechanisms by which 1,25(OH)2D
acts to promote the normal growth and mineralization of
the skeleton and the hormone’s principal target tissues
remain to be defined. A third inherited form of rickets,
X-linked hypophosphatemic rickets, has recently been
shown to result from loss of function mutations in the
PHEX gene (phosphate-regulating gene with homologies to
endopeptidases, on the X chromosome) [16]. In this dis-
ease, serum concentrations of 1,25(OH)2D are inappropri-
ately low despite the hypophosphatemia, which otherwise
can stimulate production of 1,25(OH)2D. However, the
molecular mechanisms by which loss of PHEX function
results in abnormal bone mineralization and impaired renal
tubular reabsorption of phosphate, and the relationship
between disordered regulation of phosphate and that of
1,25(OH)2D, remains to be determined. Although the
genes and their mutations responsible for three known
types of inherited rickets have now been identified, much
remains to be learned about the hormonal and ionic
regulation of the P450c1a gene and the role of 1,25(OH)2D
in calcium metabolism, bone mineralization, and cellular
differentiation. An understanding of the molecular basis
of disordered vitamin D metabolism in acquired diseases
such as chronic renal insufficiency and oncogenic osteo-
malacia also must await further study, but the availability
of new genetic reagents should facilitate the study of
vitamin D biosynthesis and action in both health and
disease.
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